bendamustine hydrochloride has been researched along with Lymphoma, B-Cell, Marginal Zone in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 16 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, A; Kurt, H; Olszewski, AJ; Zayac, AS | 1 |
| Leslie, LA | 1 |
| Alderuccio, JP; Alexander, JS; Alpert, AB; Arcaini, L; Argnani, L; Ayyappan, S; Beaven, AW; Castillo, JJ; Cencini, E; Chowdhury, SM; Edwards, D; Epperla, N; Friedberg, JW; Gaballa, S; Herrera, AF; Hess, B; Kahl, BS; Kamdar, M; Kim, SH; Kwon, D; Link, BK; Logothetis, CN; Lossos, IS; Luminari, S; Martin, P; Olszewski, AJ; Reis, IM; Saba, R; Sandoval-Sus, J; Shouse, G; Spina, M; Stefanovic, A; Torka, P; Vargas, F; Voorhees, TJ; Watkins, MP; Zhao, W; Zinzani, PL | 1 |
| Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z | 1 |
| Arcaini, L; Merli, M | 1 |
| Alhaj Moustafa, M; Borah, BJ; Cerhan, JR; Dholakia, R; Hoppe, BS; Jiang, L; Li, K; Moriarty, JP; Peterson, J; Tun, HW; Witzig, TE | 1 |
| Alderuccio, JP; Lossos, IS | 1 |
| Caces, DB; Curtis, M; Danielewicz, I; Freeman, J; García-Sancho, AM; Glazunova, V; Grigg, A; Henninger, T; Hess, G; Hou, JZ; Janssens, A; Kim, SJ; Masliak, Z; McKay, P; Merli, F; Munakata, W; Nagai, H; Nastoupil, LJ; Özcan, M; Pavlovsky, MA; Preis, M; Qin, R; Rowe, M; Salles, G; Tamegnon, M; Thieblemont, C; Wang, T | 1 |
| Cantarovich, D; Delaunay, J; Kandel, C; Ville, S | 1 |
| Hamada, T; Hatta, Y; Iriyama, N; Koike, T; Miura, K; Nakagawa, M; Nakayama, T; Takahashi, H; Takei, M; Uchino, Y | 1 |
| Minzenmayer, AN; Miranda, RN; Parekh, PK; Powell, PR | 1 |
| Argnani, L; Baumgartner, J; Broccoli, A; Carella, M; Casadei, B; Cavo, M; Coppola, PE; Hohensinner, P; Kazem, N; Koller, L; Laufer, G; Lolli, G; Morigi, A; Nanni, L; Niessner, A; Pellegrini, C; Sabattini, E; Stefoni, V; Steinlechner, B; Sulzgruber, P; Thaler, B; Wojta, J; Zinzani, PL | 1 |
| Cabras, MG; Caocci, G; Dessì, D; La Nasa, G; Mantovani, D; Moi, G; Mulas, O | 1 |
| Bartosek, AA; Cavalli, F; Di Sanzo, A; Liptrott, SJ; Miani, M; Negri, M; Stathis, A; Vanazzi, A; Vannata, B; Zucca, E | 1 |
| Hazim, AZ; Reed, GJ; Sanchez-Alvarez, C; Warrington, KJ | 1 |
| Abenhardt, W; Houet, L; Kaiser-Osterhues, A; Knauf, W; Koenigsmann, M; Maintz, C; Marschner, N; Sandner, R; Schnell, R; Tech, S; Zahn, MO | 1 |
| Arranz, R; Bargay, J; Bello, JL; Caballero, D; Canales, M; Conde, E; Domingo-Domenech, E; García, JF; García, M; Grande, C; Montalbán, C; Muntañola, A; Nicolás, C; Palomera, L; Panizo, C; Peñalver, J; Rodríguez, MJ; Salar, A; Sánchez-Blanco, JJ; Sancho, JM; Tomás, JF | 1 |
| Freedman, K; Shenoy, S | 1 |
| Bergamaschini, L; Castelli, R; Deliliers, GL | 1 |
| Bonfils, P; Rubin, F; Villeneuve, A | 1 |
| Demaria, L; Frenzel, L; Henry, J; Hermine, O; Mariette, X; Nocturne, G; Seror, R | 1 |
| Bonaldi, L; Martines, A; Nabergoj, M; Piazza, F; Pizzi, M; Scapinello, G; Semenzato, G; Trentin, L; Vio, S; Visentin, A | 1 |
| Bocchia, M; Cencini, E; Fabbri, A; Schiattone, L | 1 |
| Cheah, CY; Marlton, P; Opat, S; Trotman, J | 1 |
| Liu, Z; Mandernach, MW; Markham, M | 1 |
| Funaishi, K; Hattori, N; Matsumoto, N; Muta, T; Taniwaki, M; Yamasaki, M | 1 |
| Kiesewetter, B; Lukas, J; Mayerhoefer, ME; Müllauer, L; Raderer, M; Zielinski, CC | 1 |
| Callum, J; Lin, Y; Yan, M | 1 |
| Carter, JB; Cohen, JM; Ferry, JA; Nazarian, RM; Takvorian, RW | 1 |
| Gaitonde, S; Lu, Y; Mittal, N; Schmidt, ML; Zhu, B | 1 |
| Inayat, F; Law, JK; Myers-Gurevitch, PM; Perlman, AS; Seshan, SV | 1 |
| Barr, PM; Bernstein, SH; Carter, SJ; Friedberg, JW | 1 |
5 review(s) available for bendamustine hydrochloride and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.
Topics: Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell, Marginal Zone; Prognosis; Rituximab | 2023 |
Mucosa-associated lymphoid tissue lymphoma with intraocular and orbital involvement: case presentation and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Biopsy; Humans; Intraocular Lymphoma; Lymphoma, B-Cell, Marginal Zone; Magnetic Resonance Imaging; Male; Middle Aged; Orbital Neoplasms; Rituximab; Visual Acuity | 2018 |
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Topics: Australia; Bendamustine Hydrochloride; Disease Management; Helicobacter Infections; Helicobacter pylori; Humans; Immunotherapy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Randomized Controlled Trials as Topic; Rituximab | 2019 |
Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Biopsy; Female; Humans; Immunohistochemistry; Lymphoma, B-Cell, Marginal Zone; Nitrogen Mustard Compounds; Predictive Value of Tests; Remission Induction; Rituximab; Skin Neoplasms; Splenic Neoplasms; Time Factors; Treatment Outcome | 2015 |
5 trial(s) available for bendamustine hydrochloride and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Piperidines; Prednisone; Rituximab; Vincristine | 2023 |
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; C-Reactive Protein; CD28 Antigens; Comorbidity; Coronary Artery Bypass; Cytotoxicity, Immunologic; Elective Surgical Procedures; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Inflammation; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Postoperative Complications; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Rituximab; Survival Rate; T-Lymphocyte Subsets | 2020 |
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Recurrence; Survival Rate | 2021 |
Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Germany; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prospective Studies; Registries; Rituximab; Survival Rate | 2021 |
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Longitudinal Studies; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Rituximab; Survival Analysis | 2017 |
22 other study(ies) available for bendamustine hydrochloride and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell, Marginal Zone; Progression-Free Survival; Rituximab | 2022 |
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Herpes Zoster; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Rituximab; Young Adult | 2022 |
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography | 2022 |
Management of marginal zone lymphomas.
Topics: Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell, Marginal Zone; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rituximab | 2022 |
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Topics: Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2023 |
IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Biomarkers; Biopsy; Cell Proliferation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin kappa-Chains; Immunoglobulin Light-chain Amyloidosis; Lymphoma, B-Cell, Marginal Zone; Male; Nephrotic Syndrome; Rituximab; Treatment Outcome | 2020 |
[Transformation of CD5-positive nodal marginal zone lymphoma to diffuse large B-cell lymphoma].
Topics: Aged; Bendamustine Hydrochloride; Female; Humans; Lymph Nodes; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Rituximab | 2020 |
An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Cell Differentiation; Diagnosis, Differential; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Lymphocytes; Lymphoma, B-Cell, Marginal Zone; Mutation; Myeloid Differentiation Factor 88; Plasma Cells; Rituximab; Skin Diseases; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Blood Platelets; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prednisone; Progression-Free Survival; Proportional Hazards Models; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2021 |
Type II cryoglobulinemic vasculitis in the setting of MALT lymphoma.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Cryoglobulinemia; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Rituximab; Splenomegaly; Vasculitis | 2021 |
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Prognosis; Rituximab; Splenic Neoplasms | 2017 |
Meningeal marginal zone B-cell lymphoma: The meningioma trap.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Diagnosis, Differential; Dura Mater; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Meningeal Neoplasms; Meningioma; Middle Aged; Rituximab; Treatment Outcome | 2018 |
Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Retrospective Studies; Rituximab; Sjogren's Syndrome | 2019 |
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Lineage; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Disease Progression; Female; Genes, Immunoglobulin; Genes, myc; Humans; Immunoglobulin Heavy Chains; Lymphocytes; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Remission Induction; Rituximab; Splenic Neoplasms; Translocation, Genetic; Trisomy | 2018 |
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biopsy; Gastroscopy; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Rituximab; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Topics: Antibodies, Antiphospholipid; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rare Diseases; Rituximab; Treatment Outcome | 2019 |
Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bronchial Neoplasms; Bronchoscopy; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Mucous Membrane; Rituximab; Tomography, X-Ray Computed | 2019 |
Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nitrogen Mustard Compounds; Remission Induction; Retrospective Studies; Rituximab | 2014 |
Hyperhemolysis associated with marginal zone lymphoma.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hemoglobins; Hemolysis; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Reticulocyte Count; Rituximab; Transfusion Reaction; Treatment Outcome | 2015 |
A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Heavy Chain Disease; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Nitrogen Mustard Compounds; Prognosis; Rituximab | 2015 |
Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Colonic Neoplasms; Diagnosis, Differential; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nephrosis, Lipoid; Proteinuria; Rituximab | 2016 |
Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Nitrogen Mustard Compounds; Pneumocystis carinii; Pneumonia, Pneumocystis; Rituximab; Treatment Outcome | 2011 |